BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Clémence Dubois, Robin Dufour, Pierre Daumar, Corinne Aubel, Claire Szczepaniak, Christelle Blavignac, Emmanuelle Mounetou, Frédérique Penault-Llorca, Mahchid Bamdad. Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell linesOncotarget 2017; 8(56): 95316 doi: 10.18632/oncotarget.20517
2
Sha Li, Yijing Wu, Fei Ding, Jiapei Yang, Jing Li, Xihui Gao, Chuan Zhang, Jing Feng. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancerNanoscale 2020; 12(19): 10854 doi: 10.1039/D0NR00523A
3
Wenxian Zheng, Shuyan Han, Shantong Jiang, Xiran He, Xiaohong Li, Huirong Ding, Minhua Cao, Pingping Li. Antitumor effects of Xi Huang pills on MDA‑MB‑231 cells in�vitro and in�vivoMolecular Medicine Reports 2018;  doi: 10.3892/mmr.2018.9203
4
Heba Azzam, Rasha Kamal, Hany El-Assaly, Lamiaa I. A. Metwally. The value of dynamic contrast-enhanced MRI in differentiating triple-negative breast cancer from other subtypesEgyptian Journal of Radiology and Nuclear Medicine 2019; 50(1) doi: 10.1186/s43055-019-0118-4
5
Manal Amoury, Radoslav Mladenov, Thomas Nachreiner, Anh-Tuan Pham, Dmitrij Hristodorov, Stefano Di Fiore, Wijnand Helfrich, Alessa Pardo, Georg Fey, Michael Schwenkert, Theophilus Thepen, Fabian Kiessling, Ahmad F. Hussain, Rainer Fischer, Katharina Kolberg, Stefan Barth. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion proteinInternational Journal of Cancer 2016; 139(4): 916 doi: 10.1002/ijc.30119
6
Shahla Masood. The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicineThe Breast Journal 2020; 26(1): 27 doi: 10.1111/tbj.13728
7
Matloob Khushi, Christine L. Clarke, J. Dinny Graham. Bioinformatic analysis of cis-regulatory interactions between progesterone and estrogen receptors in breast cancerPeerJ 2014; 2: e654 doi: 10.7717/peerj.654
8
Catherine A. Powell, Mohd W. Nasser, Helong Zhao, Jacob C. Wochna, Xiaoli Zhang, Charles Shapiro, Konstantin Shilo, Ramesh K. Ganju. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stabilityOncotarget 2015; 6(8): 6373 doi: 10.18632/oncotarget.3442
9
Asadoor Amirkhani Namagerdi, Danila d’Angelo, Francesca Ciani, Carmelina Antonella Iannuzzi, Francesco Napolitano, Luigi Avallone, Michelino De Laurentiis, Antonio Giordano. Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular PathologyFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.563779
10
Silvia Cecilia Pacheco-Velázquez, Diana Xochiquetzal Robledo-Cadena, Ileana Hernández-Reséndiz, Juan Carlos Gallardo-Pérez, Rafael Moreno-Sánchez, Sara Rodríguez-Enríquez. Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell PhenotypeMolecular Pharmaceutics 2018; 15(6): 2151 doi: 10.1021/acs.molpharmaceut.8b00015
11
KeeSoo Nam, Seog-ho Son, Sunhwa Oh, Donghwan Jeon, Hyungjoo Kim, Dong-Young Noh, Sangmin Kim, Incheol Shin. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cellsOncotarget 2017; 8(22): 35804 doi: 10.18632/oncotarget.16208
12
Shang-Pen Huang, Pei-Yao Liu, Chih-Jung Kuo, Chi-Long Chen, Wei-Jiunn Lee, Yu-Hui Tsai, Yuan-Feng Lin. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancerJournal of Hematology & Oncology 2017; 10(1) doi: 10.1186/s13045-017-0481-4
13
Hana Elshaflu, Snežana Bjelogrlić, Christian D. Muller, Tamara R. Todorović, Marko Rodić, Aleksandar Marinković, Nenad R. Filipović. Co(III) complex with (E)-2-(2-(pyridine-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole: structure and activity against 2-D and 3-D cancer cell modelsJournal of Coordination Chemistry 2016; 69(22): 3354 doi: 10.1080/00958972.2016.1232404
14
Kyung-Hee Chun, Jong Hoon Park, Siting Fan. Translational Research in Breast CancerAdvances in Experimental Medicine and Biology 2017; 1026: 59 doi: 10.1007/978-981-10-6020-5_4
15
M.A. O’Rorke, L.J. Murray, J.S. Brand, N. Bhoo-Pathy. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patientsCancer Treatment Reviews 2016; 47: 12 doi: 10.1016/j.ctrv.2016.05.001
16
Mahdieh Razmi, Azra Rabbani-Chadegani, Fatemeh Hashemi-Niasari, Parinaz Ghadam. Lithium chloride attenuates mitomycin C induced necrotic cell death in MDA-MB-231 breast cancer cells via HMGB1 and Bax signalingJournal of Trace Elements in Medicine and Biology 2018; 48: 87 doi: 10.1016/j.jtemb.2018.03.011
17
Yubing Zhou, Chao Han, Duolu Li, Zujiang Yu, Fengmei Li, Feng Li, Qi An, Huili Bai, Xiaojian Zhang, Zhenfeng Duan, Quancheng Kan. Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growthScientific Reports 2015; 5(1) doi: 10.1038/srep10433
18
Aurore Claude-Taupin, Leïla Fonderflick, Thierry Gauthier, Laura Mansi, Jean-René Pallandre, Christophe Borg, Valérie Perez, Franck Monnien, Marie-Paule Algros, Marc Vigneron, Pascale Adami, Régis Delage-Mourroux, Paul Peixoto, Michael Herfs, Michaël Boyer-Guittaut, Eric Hervouet. ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer PhenotypesCells 2018; 7(12): 248 doi: 10.3390/cells7120248
19
Alessandra Longo, Mariangela Librizzi, Irina Chuckowree, Christine Baltus, John Spencer, Claudio Luparello. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer CellsMolecules 2015; 20(6): 9879 doi: 10.3390/molecules20069879
20
Kamal Ahmed, Alexey Koval, Jiabin Xu, Alexandre Bodmer, Vladimir L. Katanaev. Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitorCancer Letters 2019; 449: 45 doi: 10.1016/j.canlet.2019.02.018
21
Rittwika Bhattacharya, Koyel Banerjee, Nupur Mukherjee, Minakshi Sen, Ashis Mukhopadhyay. From molecular insight to therapeutic strategy: The holistic approach for treating triple negative breast cancerPathology - Research and Practice 2017; 213(3): 177 doi: 10.1016/j.prp.2017.01.001
22
XIANGNAN KONG, XIA DING, QIFENG YANG. Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cellsInternational Journal of Oncology 2015; 46(5): 2047 doi: 10.3892/ijo.2015.2932
23
Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang, Roberto R. Rosato. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs Breast Cancer Research 2020; 22(1) doi: 10.1186/s13058-020-01280-z
24
Meaghan Krohe, Yanni Hao, Roger E. Lamoureux, Nina Galipeau, Denise Globe, Catherine Foley, Iyar Mazar, Jeffrey Solomon, Alan L. Shields. Patient-Reported Outcomes in Metastatic Breast Cancer: A Review of Industry-Sponsored Clinical TrialsBreast Cancer: Basic and Clinical Research 2016; 10: BCBCR.S39385 doi: 10.4137/BCBCR.S39385
25
Gamze Guney Eskiler, Gulsah Cecener, Unal Egeli, Berrin Tunca. Triple negative breast cancer: new therapeutic approaches andBRCAstatusAPMIS 2018; 126(5): 371 doi: 10.1111/apm.12836
26
Manuela Labbozzetta, Monica Notarbartolo, Paola Poma. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of ViewInternational Journal of Molecular Sciences 2020; 21(9): 3070 doi: 10.3390/ijms21093070
27
S Cowherd, L D Miller, S A Melin, S Akman, S Isom, J Cole, A Pullikuth, J A Lawrence. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancerCancer Biology & Therapy 2015; 16(5): 678 doi: 10.1080/15384047.2015.1026481
28
Dong Hwan Kim, Bokyung Sung, Jin-Ah Kim, Yong Jung Kang, Seong Yeon Hwang, Na-Lam Hwang, Hongsuk Suh, Yung Hyun Choi, Eunok Im, Hae Young Chung, Nam Deuk Kim. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft modelInternational Journal of Oncology 2017; 51(2): 715 doi: 10.3892/ijo.2017.4058
29
H. Portha, C. Jankowski, M. Cortet, I. Desmoulins, E. Martin, V. Lorgis, L. Arnould, C. Coutant. Tumeurs localisées du sein triple négatives en 2016 : définitions et prise en chargeGynécologie Obstétrique & Fertilité 2016; 44(9): 492 doi: 10.1016/j.gyobfe.2016.06.014
30
Murugan Kalimutho, Kate Parsons, Deepak Mittal, J. Alejandro López, Sriganesh Srihari, Kum Kum Khanna. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn DiseaseTrends in Pharmacological Sciences 2015; 36(12): 822 doi: 10.1016/j.tips.2015.08.009
31
Jörg B. Engel. GHRH-antagonists in TNBCOncotarget 2015; 6(4): 1898 doi: 10.18632/oncotarget.3271
32
Haonan Li, Fanxing Xu, Gang Gao, Xiang Gao, Bo Wu, Chao Zheng, Peng Wang, Zhanlin Li, Huiming Hua, Dahong Li. Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancerRedox Biology 2020; 34: 101564 doi: 10.1016/j.redox.2020.101564
33
SEUNG-YOUN JUNG, JAE YOUN YI, MI-HYOUNG KIM, KYUNG-HEE SONG, SEONG-MOOK KANG, JIYEON AHN, SANG-GU HWANG, KY-YOUB NAM, JIE-YOUNG SONG. IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signalingOncology Reports 2015; 34(5): 2731 doi: 10.3892/or.2015.4249
34
Cassandre Yip, Pierre Foidart, Joan Somja, Alice Truong, Mehdi Lienard, Emilie Feyereisen, Hélène Schroeder, Stéphanie Gofflot, Anne-Françoise Donneau, Joëlle Collignon, Philippe Delvenne, Nor Eddine Sounni, Guy Jerusalem, Agnès Noël. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinibBritish Journal of Cancer 2017; 116(6): 742 doi: 10.1038/bjc.2017.23
35
Jiajing Chen, Yuenong Qin, Chenping Sun, Wei Hao, Shuai Zhang, Yi Wang, Juan Chen, Lixin Chen, Yiying Ruan, Sheng Liu. Clinical study on postoperative triple-negative breast cancer with Chinese medicineMedicine 2018; 97(25): e11061 doi: 10.1097/MD.0000000000011061
36
Fukai Wang, Xiang Song, Shuangshuang Ma, Chenyu Liu, Xiaohui SUN, Xinzhao Wang, Zhaoyun Liu, Dong Liang, Zhiyong Yu. The treatment role of Cyperus rotundus L. to triple-negative breast cancer cellsBioscience Reports 2019; 39(6) doi: 10.1042/BSR20190502
37
Keith O’Brien, Michelle C. Lowry, Claire Corcoran, Vanesa G. Martinez, Melissa Daly, Sweta Rani, William M. Gallagher, Marek W. Radomski, Roderick A.F. MacLeod, Lorraine O’Driscoll. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivityOncotarget 2015; 6(32): 32774 doi: 10.18632/oncotarget.5192
38
Ming-juan Liao, Mei-na Ye, Rui-juan Zhou, Jia-yu Sheng, Hong-feng Chen. Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer XenograftsEvidence-Based Complementary and Alternative Medicine 2014; 2014: 1 doi: 10.1155/2014/628712
39
XUHONG ZHU, QIN LI, SHUANG LI, BOTE CHEN, HAIDONG ZOU. HIF-1α decoy oligodeoxynucleotides inhibit HIF-1α signaling and breast cancer proliferationInternational Journal of Oncology 2015; 46(1): 215 doi: 10.3892/ijo.2014.2715
40
Renata Danielle Sicchieri, Willian Abraham da Silveira, Larissa Raquel Mouro Mandarano, Tatiane Mendes Gonçalves de Oliveira, Hélio Humberto Angotti Carrara, Valdair Francisco Muglia, Jurandyr Moreira de Andrade, Daniel Guimarães Tiezzi. ABCG2 is a potential marker of tumor-initiating cells in breast cancerTumor Biology 2015; 36(12): 9233 doi: 10.1007/s13277-015-3647-0
41
Magdalena Absmaier, Rudolf Napieralski, Tibor Schuster, Michaela Aubele, Axel Walch, Viktor Magdolen, Julia Dorn, Eva Gross, Nadia Harbeck, Aurelia Noske, Marion Kiechle, Manfred Schmitt. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patientsInternational Journal of Oncology 2018;  doi: 10.3892/ijo.2018.4241
42
Xiao-Lin Zhang, Na Liu, Shan-Fan Weng, Hong-Sheng Wang. Bisphenol A Increases the Migration and Invasion of Triple-Negative Breast Cancer Cells via Oestrogen-related Receptor GammaBasic & Clinical Pharmacology & Toxicology 2016; 119(4): 389 doi: 10.1111/bcpt.12591
43
Sarita Das, Neha Tripathi, Sumit Siddharth, Anmada Nayak, Deepika Nayak, Chinmayee Sethy, Prasad V. Bharatam, Chanakya Nath Kundu. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axisApoptosis 2017; 22(10): 1205 doi: 10.1007/s10495-017-1400-4
44
Shahla Masood. Breast Cancer Subtypes: Morphologic and Biologic CharacterizationWomen's Health 2016; 12(1): 103 doi: 10.2217/whe.15.99
45
Zining Jin, Wenqian Wang, Nan Jiang, Lei Zhang, Yiming Li, Xiaoyin Xu, Shouliang Cai, Liang Wei, Xuhong Liu, Guanglei Chen, Yizhen Zhou, Cheng Liu, Zhan Li, Feng Jin, Bo Chen, Ying-Jan Wang. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant ChemotherapyPLOS ONE 2015; 10(7): e0130286 doi: 10.1371/journal.pone.0130286
46
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J. Rosol, Xiyun Deng. Triple-negative breast cancer: is there a treatment on the horizon?Oncotarget 2017; 8(1): 1913 doi: 10.18632/oncotarget.12284
47
Long Ge, Yan Tang, Qiu-Ning Zhang, Jin-Hui Tian, Xiao-Hu Wang, Dawid Pieper, Bei Pan, Lun Li, Juan Ling, Zhi-Tong Bing, Ke-Hu Yang. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancerOncotarget 2017; 8(35): 59539 doi: 10.18632/oncotarget.19102
48
Y. L. Xu, R. Yao, J. Li, Y. D. Zhou, F. Mao, B. Pan, Q. Sun. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancerCancer Chemotherapy and Pharmacology 2017; 79(6): 1205 doi: 10.1007/s00280-017-3319-4
49
Zehedina Khatun, Md Nurunnabi, Md Nafiujjaman, Gerald R. Reeck, Haseeb A. Khan, Kwang Jae Cho, Yong-kyu Lee. A hyaluronic acid nanogel for photo–chemo theranostics of lung cancer with simultaneous light-responsive controlled release of doxorubicinNanoscale 2015; 7(24): 10680 doi: 10.1039/C5NR01075F
50
Hyosun Kim, Jihyoung Cho, Sun Young Kwon, Sun Hee Kang. Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinomaAnnals of Surgical Treatment and Research 2016; 90(1): 1 doi: 10.4174/astr.2016.90.1.1
51
Hossam Taha Mohamed, Eslam A. El-Ghonaimy, Mohamed El-Shinawi, Mohamed Hosney, Martin Götte, Wendy A. Woodward, Tahani El-Mamlouk, Mona Mostafa Mohamed. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2Toxicology and Applied Pharmacology 2020; 401: 115092 doi: 10.1016/j.taap.2020.115092
52
Hassan Y. Ebrahim, Mohamed M. Mohyeldin, Mohammad M. Hailat, Khalid A. El Sayed. (1 S ,2 E ,4 S ,7 E ,11 E )-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignanciesBioorganic & Medicinal Chemistry 2016; 24(22): 5748 doi: 10.1016/j.bmc.2016.09.032
53
Juan Garona, Marina Pifano, Maria B. Pastrian, Daniel E. Gomez, Giselle V. Ripoll, Daniel F. Alonso. Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour modelsClinical & Experimental Metastasis 2016; 33(6): 589 doi: 10.1007/s10585-016-9799-5
54
Ke Wang, Xue Zhu, Kai Zhang, Yongxiang Yin, Yu Chen, Ting Zhang. Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1αJournal of Biochemical and Molecular Toxicology 2018; 32(3): e22039 doi: 10.1002/jbt.22039
55
Francisca Guardiola-Serrano, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Maitane Ibarguren, David J. López, Silvia Terés, María Alonso-Sande, Mónica Higuera, Manuel Torres, Xavier Busquets, Pablo V. Escribá. The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and AktOncotarget 2019; 10(26): 2486 doi: 10.18632/oncotarget.26824
56
Yu Ran Lee, Myoung Soo Park, Hee Kyoung Joo, Ki Mo Kim, Jeryong Kim, Byeong Hwa Jeon, Sunga Choi. Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivoScientific Reports 2018; 8(1) doi: 10.1038/s41598-018-27025-9
57
Sergio Andrés Torres-Pérez, María del Pilar Ramos-Godínez, Eva Ramón-Gallegos. Glycosylated one-step PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231Journal of Drug Delivery Science and Technology 2020; 58: 101769 doi: 10.1016/j.jddst.2020.101769
58
Sabine Heublein, Doris Mayr, Alfons Meindl, Alexandra Kircher, Udo Jeschke, Nina Ditsch. Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosisJournal of Experimental & Clinical Cancer Research 2017; 36(1) doi: 10.1186/s13046-017-0517-1
59
Wenxian Zheng, Shuyan Han, Shantong Jiang, Lina Pang, Xiaohong Li, Xijuan Liu, Minhua Cao, Pingping Li. Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell lineBiomedical Reports 2016; 5(5): 559 doi: 10.3892/br.2016.769
60
Anna Wawruszak, Jarogniew J. Luszczki, Joanna Kalafut, Karolina Okla, Marta Halasa, Adolfo Rivero-Muller, Andrzej Stepulak. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity—An Isobolographic AnalysisInternational Journal of Molecular Sciences 2019; 20(15): 3663 doi: 10.3390/ijms20153663
61
Charles Johannessen, Line Moi, Yury Kiselev, Mona Irene Pedersen, Stig Manfred Dalen, Tonje Braaten, Lill-Tove Busund, Aamir Ahmad. Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancerPLOS ONE 2017; 12(10): e0186658 doi: 10.1371/journal.pone.0186658
62
Cornelia Braicu, Valentina Pileczki, Laura Pop, Roxana Cojocneanu Petric, Sergiu Chira, Eve Pointiere, Patriciu Achimas-Cadariu, Ioana Berindan-Neagoe, Sumitra Deb. Dual Targeted Therapy with p53 siRNA and Epigallocatechingallate in a Triple Negative Breast Cancer Cell ModelPLOS ONE 2015; 10(4): e0120936 doi: 10.1371/journal.pone.0120936
63
Mohd. Kamil Hussain, Deependra Kumar Singh, Akhilesh Singh, Mohd. Asad, Mohd. Imran Ansari, Mohammad Shameem, Shagun Krishna, Guru R. Valicherla, Vishal Makadia, Sanjeev Meena, Amit Laxmikant Deshmukh, Jiaur R. Gayen, Mohammad Imran Siddiqi, Dipak Datta, Kanchan Hajela, Dibyendu Banerjee. A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer modelsScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10864-3
64
Shuang Li, Qingzhu Wei, Qin Li, Bin Zhang, Qiang Xiao. Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancerCancer Biology & Therapy 2015; 16(6): 866 doi: 10.1080/15384047.2015.1040958
65
Blessing I Bassey-Archibong, Lyndsay G A Rayner, Shawn M Hercules, Craig W Aarts, Anna Dvorkin-Gheva, Jonathan L Bramson, John A Hassell, Juliet M Daniel. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cellsCell Death & Disease 2017; 8(3): e2689 doi: 10.1038/cddis.2017.92